PF-07104091 as a Single Agent and in Combination Therapy
A phase 2 trial of Palbociclib, Fulvestrant, Letrozole in small-cell lung cancer and ovarian cancer, run by Pfizer, active and no longer recruiting.
Overview
PF-07104091 as a Single Agent and in Combination Therapy is a phase 2 interventional study registered as NCT04553133 by Pfizer, with 157 participants enrolled, started 2020-09-16 and due to reach its primary completion in 2026-12-31. Interventions recorded: PF-07104091 monotherapy dose escalation, PF-07104091 + palbociclib + fulvestrant, PF-07104091 + palbociclib + letrozole, PF-07104091 monotherapy dose expansion (ovarian), PF-07104091 monotherapy dose expansion (SCLC). Conditions listed: Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of PF-07248144 in Advanced or Metastatic Solid Tumors
Shares Letrozole (and other aromatase inhibitors), Palbociclib, Fulvestrant, Pfizer (incl. Seagen).
- TrialStudy for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
Shares Palbociclib, Fulvestrant, Pfizer (incl. Seagen).
- TrialStudy to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
Shares Letrozole (and other aromatase inhibitors), Fulvestrant, Pfizer (incl. Seagen).
- TrialDNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
Shares Palbociclib, Fulvestrant.
- TrialSNV4818 in Participants With Advanced Solid Tumors
Shares Palbociclib, Fulvestrant.
- TrialStudy of AVZO-021 in Patients With Advanced Solid Tumors
Shares Letrozole (and other aromatase inhibitors), Palbociclib, Fulvestrant, Ovarian cancer.
- TrialStudy of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Shares Letrozole (and other aromatase inhibitors), Fulvestrant.
- TrialVepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer
Shares Palbociclib, Pfizer (incl. Seagen).